** Shares of drug developer eFFECTOR Therapeutics Inc
EFTR.O rise 62.80% to $0.86 premarket, among top pct. gainers
across U.S. exchanges
** Announced positive interim data from a mid-stage study
evaluating combination therapy of its zotatifin in patients with
a type of breast cancer
** Says partial responses observed in 5 of 19 evaluable
patients treated with 0.07 mg/kg dose of zotatifin combined with
AstraZeneca Plc's AZN.L fulvestrant and Eli Lilly and Co's
LLY.N abemaciclib
** Adds partial response observed in 1 of 3 patients
treated with 0.1 mg/kg dose of combined with fulvestrant
** Both combinations were generally well tolerated - EFTR
** Plans to report data from the completed dose escalation
in H2
** Up to last close, stock up ~23% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))